Share Price:

APNASPENAspen Pharmacare Hldgs16900-151 (-0.89%)

Aspen will be in a closed period from 1 January 2025 until the publication of the Interim Results on the JSE SENS platform on 3 March 2025.

Business Segment

Prescription

Products which generally require a prescription from a healthcare professional. Primary therapeutic areas are anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids.

Overview

Eltroxin Imuran Lipitor Lyrica Meticorten Purinethol

Thyroid hormone

Immunosuppressant

Cardiovascular

Anticonvulsant
and neuropathy

Corticosteroid

Oncology

Revenue by segment (%)

25%

of Group revenue

36%

of Group gross profit

Revenue
Revenue 2024
R’million
2023
R’million
%Change
Reported
CER

Africa Middle East

4 242

3 876

9

9

Americas

2 832
1 801

57

42

Australasia

2 618

2 713

(4)

(6)

Europe CIS

991

989

-

(7)
Asia
697

542

29

24

Total

11 380

9 921

15

11

Gross profit (%)

60,9

60,7

Prescription brands achieved robust growth of 15%, with revenue reaching R11 380 million. This was primarily driven by the Americas, which posted a 57% increase supported by both organic and acquisition-led growth. Asia grew by 29%, benefiting from a 7% increase in organic growth alongside acquisitive gains. Africa Middle East, the largest region in this segment, reported strong organic growth of 9%. Europe CIS remained flat while Australasia experienced a 4% decline due to regulated price reductions in Australia.
The gross profit margin rose to 60,9% (FY2023: 60,7%), with the positive impact of the favourable sales mix more than offsetting the effects of regulated price cuts in Australia.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.